Analysts at BTIG Research assumed coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) in a research report issued to clients and investors on Wednesday. The firm set a “buy” rating and a $16.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 93.70% from the stock’s current price.

A number of other analysts have also issued reports on the company. HC Wainwright initiated coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a report on Wednesday. They issued a “buy” rating and a $12.00 price target for the company. Piper Jaffray Companies initiated coverage on ASLAN PHARMACEUTICALS ADR REP 5 in a report on Wednesday. They issued an “overweight” rating for the company.

Shares of ASLAN PHARMACEUTICALS ADR REP 5 opened at $8.26 on Wednesday, according to MarketBeat Ratings. ASLAN PHARMACEUTICALS ADR REP 5 has a 52-week low of $5.08 and a 52-week high of $9.51.

About ASLAN PHARMACEUTICALS ADR REP 5

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm’s portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways.

Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.